The pharmaceutical company announced that it had received final approval from the US Food and Drug Administration (USFDA) for Erythromycin Tablets USP, 250 mg and 500 mg. Erythromycin tablets USP are used to prevent and treat infections in various parts of the body, such as the respiratory tract, skin, and intestinal tract, as well as acute pelvic inflammatory disease, legionnaire’s disease, pertussis, and syphilis. The aforementioned medication is the same as the reference listed drug (RLD), Erythromycin tablets. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, according to the pharma company (India).
Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of $25.1 million in the United States in December 2022, according to IQVIA MAT data. As of December 31, 2022, the group had 350 approvals and had filed over 440 ANDAs since the filing process began in FY 2003-04. Zydus Lifesciences is a global lifesciences company focused on discovery that discovers, develops, manufactures, and markets a wide range of healthcare therapies. The drugmaker’s consolidated net profit increased 24.48% to Rs 622.9 crore in Q3 FY23 over Q3 FY22, thanks to a 19.85% increase in total revenue from operations to Rs 4,362.3 crore.